{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T05:22:31Z","timestamp":1793510551993,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["MS-1610-37115"],"award-info":[{"award-number":["MS-1610-37115"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["R-1902-33620"],"award-info":[{"award-number":["R-1902-33620"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cct.2025.108117","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:23:21Z","timestamp":1761186201000},"page":"108117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants"],"prefix":"10.1016","volume":"159","author":[{"given":"Ellen M.","family":"Mowry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Meador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Borazanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Silversteen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Esch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Tornes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Kaisey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Sicotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharama","family":"Pawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirisham","family":"Gyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torge","family":"Rempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Z.","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana Zhovtis","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Carass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornusa","family":"Chalayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason","family":"Kruse-Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monilola","family":"Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Dewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ogburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Cassard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cct.2025.108117_bb0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11591150-000000000-00000","article-title":"Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners","volume":"4","author":"Larocca","year":"2011","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.cct.2025.108117_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.WNL.0000101724.93433.00","article-title":"Change in MS-related disability in a population-based cohort: a 10-year follow-up study","volume":"62","author":"Pittock","year":"2004","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.cct.2025.108117_bb0015","first-page":"591","article-title":"Multiple sclerosis and mobility restriction","volume":"64","author":"Baum","year":"1983","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"18","key":"10.1016\/j.cct.2025.108117_bb0020","doi-asserted-by":"crossref","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs","volume":"98","author":"Bebo","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.cct.2025.108117_bb0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ncl.2017.08.006","article-title":"Progressive forms of multiple sclerosis: distinct entity or age-dependent phenomena","volume":"36","author":"Zeydan","year":"2018","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.cct.2025.108117_bb0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41582-023-00838-7","article-title":"Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis","volume":"19","author":"Magliozzi","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.cct.2025.108117_bb0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/WCO.0000000000000818","article-title":"Mechanisms underlying progression in multiple sclerosis","volume":"33","author":"Absinta","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.cct.2025.108117_bb0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2023.06.004","article-title":"Highly effective therapy versus escalation approaches in early multiple sclerosis: what is the future of multiple sclerosis treatment?","volume":"42","author":"Bou Rjeily","year":"2024","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.cct.2025.108117_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103555","article-title":"Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: a mediation analysis","volume":"59","author":"Chen","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.cct.2025.108117_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/WNL.0000000000002830","article-title":"Assessing response to interferon-\u03b2 in a multicenter dataset of patients with MS","volume":"87","author":"Sormani","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.cct.2025.108117_bb0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era","volume":"80","author":"University of California","year":"2016","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.cct.2025.108117_bb0060","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/1352458518770088","article-title":"New versus old: implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis","volume":"25","author":"McNicholas","year":"2019","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.cct.2025.108117_bb0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.cct.2025.108117_bb0070","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.cct.2025.108117_bb0075","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1212\/WNL.0000000000011242","article-title":"Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years","volume":"96","author":"Kalincik","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cct.2025.108117_bb0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.cct.2025.108117_bb0085","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different National Strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.cct.2025.108117_bb0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cct.2025.108117_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231221331","article-title":"Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies","volume":"17","author":"Butzkueven","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.cct.2025.108117_bb0100","author":"Available at"},{"key":"10.1016\/j.cct.2025.108117_bb0105","author":"Available at"},{"issue":"18","key":"10.1016\/j.cct.2025.108117_bb0110","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s40265-020-01422-9","article-title":"The development of Cladribine tablets for the treatment of multiple sclerosis: a comprehensive review","volume":"80","author":"Rammohan","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.cct.2025.108117_bb0115","article-title":"Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with Natalizumab: a systematic review","volume":"13","author":"Vivekanandan","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.cct.2025.108117_bb0120","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.cct.2025.108117_bb0125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/13524585211026272","article-title":"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry","volume":"28","author":"Spelman","year":"2022","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.cct.2025.108117_bb0130","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51408","article-title":"DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France","volume":"8","author":"Sormani","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.cct.2025.108117_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103636","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.cct.2025.108117_bb0140","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3174\/ajnr.A4539","article-title":"Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis","volume":"37","author":"Traboulsee","year":"2016","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"11","key":"10.1016\/j.cct.2025.108117_bb0145","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.cct.2025.108117_bb0150","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/1352458509106212","article-title":"Assessing disability progression with the multiple sclerosis functional composite","volume":"15","author":"Rudick","year":"2009","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.cct.2025.108117_bb0155","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1177\/1352458514527180","article-title":"Composite end points to assess delay of disability progression by MS treatments","volume":"20","author":"Zhang","year":"2014","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.cct.2025.108117_bb0160","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon \u03b2-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.cct.2025.108117_bb0165","first-page":"214","article-title":"Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards. Lifetime data anal. 2019 Jul;25(3):439-468. doi: 10.1007\/s10985-018-9428-5. Epub 2018 Feb 28","volume":"26","author":"D\u00edaz","year":"2020","journal-title":"Erratum in: Lifetime Data Anal."},{"issue":"5","key":"10.1016\/j.cct.2025.108117_bb0170","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"9","key":"10.1016\/j.cct.2025.108117_bb0175","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.1212\/WNL.0000000000013230","article-title":"Enrollment of non-white participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: a systematic review","volume":"98","author":"Onuorah","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.cct.2025.108117_bb0180","author":"Available at"},{"issue":"19","key":"10.1016\/j.cct.2025.108117_bb0185","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1212\/WNL.0b013e3182918cc2","article-title":"Incidence of multiple sclerosis in multiple racial and ethnic groups","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.cct.2025.108117_bb0190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","article-title":"Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis","volume":"9","author":"Fogarty","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.cct.2025.108117_bb0195","article-title":"Outcome measures in multiple sclerosis","volume":"2014","author":"Bermel","year":"2014","journal-title":"Mult. Scler. Int."},{"issue":"Pt 5","key":"10.1016\/j.cct.2025.108117_bb0200","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/brain\/123.5.1027","article-title":"Kurtzke scales revisited: the application of psychometric methods to clinical intuition","volume":"123","author":"Hobart","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.cct.2025.108117_bb0205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.cct.2025.108117_bb0210","series-title":"International Conference on Medical Image Computing and Computer-Assisted Intervention","first-page":"720","article-title":"A disentangled latent space for cross-site MRI harmonization","author":"Dewey","year":"2020"},{"key":"10.1016\/j.cct.2025.108117_bb0215","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mri.2023.01.012","article-title":"ESPRESO: an algorithm to estimate the slice profile of a single magnetic resonance image","volume":"98","author":"Han","year":"2023","journal-title":"Magn. Reson. Imaging"},{"key":"10.1016\/j.cct.2025.108117_bb0220","series-title":"International Workshop on Simulation and Synthesis in Medical Imaging","first-page":"118","article-title":"Self-supervised super-resolution for anisotropic MR images with and without slice gap","author":"Remedios","year":"2023"},{"key":"10.1016\/j.cct.2025.108117_bb0225","series-title":"International Workshop on Simulation and Synthesis in Medical Imaging","first-page":"34","article-title":"Beyond MR image harmonization: Resolution matters too","author":"Hays","year":"2024"},{"key":"10.1016\/j.cct.2025.108117_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.compmedimag.2023.102285","article-title":"HACA3: a unified approach for multi-site MR image harmonization","volume":"109","author":"Zuo","year":"2023","journal-title":"Comput. Med. Imaging Graph."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425003118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425003118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:34:59Z","timestamp":1780918499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425003118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"alternative-id":["S1551714425003118"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.108117","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.108117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108117"}}